Overview
BERG, now the core technology platform of BPGbio, represents the frontier of AI in life sciences as of 2026. Its technical architecture is built around the Interrogative Biology® platform, which utilizes a 'hypothesis-free' approach to biological research. Unlike traditional AI models that rely on existing scientific literature (which may contain biases), BERG's Bayesian-based Causal AI engine analyzes raw multi-omics data—including proteomics, lipidomics, and metabolomics—from both healthy and diseased human samples. This allows the system to map the 'interactome' of a cell and identify the actual drivers of disease rather than simple correlations. By 2026, BERG's positioning has shifted from a pure service provider to a strategic clinical-stage partner, leveraging its bAIcis® high-performance computing environment to accelerate drug development in oncology, neurology, and rare diseases. The platform is notable for its ability to create 'Digital Twins' of biological systems, enabling researchers to simulate drug-target interactions with high fidelity before entering wet-lab validation, significantly reducing the 'Eroom's Law' effect in pharmaceutical R&D.